Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (10639)	10/31/2002 11:35:01 AM
From: afrayem onigwecher	Read Replies (4) \| Respond to of 19428

GeneMax Corp. Announces Appointment of Dr. Barbara Seliger, Leading Cancer Immunologist, to Its Scientific Advisory Board BLAINE, Wash., Oct. 31 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) announces today that Professor Dr. Barbara Seliger has joined the Company's Scientific Advisory Board. Dr. Seliger is Professor of Immunology and Pathophysiology at the Johannes Gutenberg University, Department of Internal Medicine in Mainz, Germany. Dr. Seliger is a world expert in tumor biology, tumor immunology and immunotherapy, including work on TAP (transporters associated with antigen processing), the area of GeneMax's lead product development, and in HLA class I antigen downregulation in human cancers. She has focused on mechanisms of immune escape, the development of anti-tumor vaccines, immunology and molecular biology of renal cell carcinoma and the identification of tumor-associated antigens as well as novel therapeutic and prognostic markers using proteome-based technologies. Dr. Seliger has published some 80 papers in these areas. Professor Dr. Seliger said, "I believe that GeneMax's core technologies involving TAP are entirely innovative and have the potential to alter the course of immunotherapies for tumors and other areas as well. It is a privilege to be involved in this ground breaking work and to help facilitate the upcoming clinical trials." Dr. Seliger graduated from the Georg August-University in Gottingen in Germany and performed her PhD thesis at the Beatson Institute for Cancer Research, Glasgow, Scotland and the Heinrich-Pette-Institute, Hamburg, Germany. She was post-doctoral fellow at the Max-Planck Institute for Experimental Medicine in Gottingen before she became Assistant Professor for Molecular Biology at the Ludwig Institute and Karolinska Institute in Stockholm, Sweden. In 1990, she was appointed Visiting Professor of Immunology at the Christian Albrechts-University of Kiel, Germany, before she moved to Mainz and granted as a University-Professor at the University of Mainz. In addition, she became a Visiting Professor at the Weizman Institute in Rehovot, Israel and is appointed a Guest Professor at the Karolinska Institute in Stockholm, Sweden. In April 2002, she was offered a Chair for Clinical Immunology at the Martin-Luther University in Halle, Germany. Dr. Seliger is active in different national organizations and is reviewer for more than 15 international journals, including the Cancer Research, International Journal of Cancer, Lancet, The Journal of the National Cancer Institute and Trends in Immunology. Ronald L. Handford, President & CEO of GeneMax, said, "Dr. Seliger will be a strong addition to our Scientific Advisory Board. Her expertise in our core product development areas, as well as her European presence and international affiliations, will be a significant asset to the company." Dr. Seliger joins a notable team on the GeneMax Scientific Advisory Board including Dr. Wilfred A. Jefferies, GeneMax's Chief Scientific Officer and Professor of Biotechnology at the University of British Columbia and inventor of GeneMax's lead technologies, Dr. Soldano Ferrone, Chairman of the Department of Immunology at the Roswell Park Cancer Institute in Buffalo, New York, Dr. James Hogg, Professor of Pathology at the University of British Columbia, Dr. Victor Ling, Vice President Research at the B.C. Cancer Agency and Dr. Bernard Moss of Bethesda, Maryland, a member of the National Academy of Science and an expert in the field of expression vector systems. About GeneMax: GeneMax is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.